Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rasagiline.

M Asif A Siddiqui1, Greg L Plosker

  • 1Adis International Limited, Auckland 1311, New Zealand. demail@adis.co.nz

Drugs & Aging
|January 25, 2005
PubMed
Summary
This summary is machine-generated.

Rasagiline, a selective monoamine-oxidase type B inhibitor, effectively treats early Parkinson's disease and reduces "off" time in advanced stages. It demonstrates neuroprotective effects and is well-tolerated, offering a valuable therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Asenapine: A Review in Schizophrenia.

CNS drugs·2016
Same author

AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.

Drugs·2015
Same author

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.

Drugs·2015
Same author

Acamprosate: A Review of Its Use in Alcohol Dependence.

Drugs·2015
Same author

Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain.

Clinical drug investigation·2015
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Neurology

Background:

  • Rasagiline is a selective, irreversible MAO-B inhibitor investigated for Parkinson's disease (PD).
  • It exhibits neuroprotective properties independent of MAO inhibition.
  • Rasagiline lacks amphetamine-like metabolites, unlike selegiline.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of rasagiline as monotherapy for early PD.
  • To assess rasagiline's effect on symptom progression and functional decline in early PD.
  • To determine rasagiline's efficacy in reducing "off" time in advanced PD patients on levodopa therapy.

Main Methods:

  • Randomized, double-blind trials were conducted for early PD monotherapy (n=404) and advanced PD add-on therapy (n=1159).

Related Experiment Videos

  • Functional decline was assessed by comparing immediate rasagiline treatment versus delayed treatment (n=371).
  • Efficacy was measured by symptom worsening, functional decline, and reduction in "off" time.

    • Main Results:

    • Rasagiline monotherapy (1-2 mg/day) significantly attenuated symptom worsening in early PD compared to placebo.
    • Patients treated with rasagiline showed less functional decline than those with delayed treatment.
    • In advanced PD, rasagiline (0.5-1 mg/day) significantly reduced daily "off" time, with efficacy comparable to entacapone.

    Conclusions:

    • Rasagiline is effective as monotherapy for early Parkinson's disease, slowing symptom progression.
    • Rasagiline provides significant benefits for advanced Parkinson's disease by reducing "off" time.
    • Rasagiline is generally well-tolerated in clinical trials for both early and advanced PD stages.